Info@diaspoint.nl

South Africa will begin rolling out Lenacapavir, a new HIV prevention injection, through the public health system in early 2026, marking a major advancement in efforts to curb new infections. The twice-yearly injectable drug, proven effective in clinical trials—many conducted locally—offers a discreet and practical alternative to daily pills.

According to Dr. Joel Steingo of TB HIV Care, Lenacapavir could be a breakthrough in preventing HIV, especially as global funding for HIV programmes declines. The drug targets high-risk groups, including adolescent girls, sex workers, men who have sex with men, and people who inject drugs.

Steingo highlighted that Lenacapavir’s ability to be stored at room temperature makes it well-suited for rural and hard-to-reach areas. While implementation will require stronger logistics and healthcare training, the new injection offers renewed hope in reducing HIV transmission and reinvigorating prevention efforts across South Africa.